<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2928">
  <stage>Registered</stage>
  <submitdate>24/09/2010</submitdate>
  <approvaldate>24/09/2010</approvaldate>
  <nctid>NCT01209793</nctid>
  <trial_identification>
    <studytitle>Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers</studytitle>
    <scientifictitle>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety and Tolerability of Intravenously Administered REGN846 (SAR302352) in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>R846-HV-1007</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - REGN846

Experimental: Dose 1 - (3:1, active: placebo)

Experimental: Dose 2 - (3:1, active: placebo)

Experimental: Dose 3 - (3:1, active: placebo)

Experimental: Dose 4 - (3:1, active: placebo)

Experimental: Dose 5 - (3:1, active: placebo)


Other interventions: REGN846
5 IV cohorts (Dose 1, 2, 3, 4, 5)

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence and severity of adverse events</outcome>
      <timepoint>Baseline through end of study</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>PK profile</outcome>
      <timepoint>Baseline through end of study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity</outcome>
      <timepoint>Visits 2, 8, 10 and 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy men and women between the ages of 18 and 65; women must be postmenopausal or
             surgically sterile

          -  Body Mass Index (BMI) between 18.0 and 30.0 kg/m2, inclusive

          -  Normal vital signs after resting in a sitting position for 5 minutes:

          -  Normal standard 12-lead ECG

          -  Willing and able to comply with clinic visits and study-related procedures

          -  Provide signed informed consent

          -  Able to understand and complete study-related questionnaires</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Current or prior history of smoking

          -  Any illness or condition that would adversely affect the subject's participation in
             this study

          -  Hospitalization within 60 days of the screening visit

          -  Any clinically significant abnormalities observed during the screening visit

          -  History of or positive human immunodeficiency virus (HIV) screen result at the
             screening visit

          -  History of positive blood test for hepatitis B/hepatitis C or positive hepatitis
             screen result at the screening visit

          -  History of positive drug screen result for drug or alcohol abuse within a year prior
             to the screening visit

          -  Known sensitivity to any of the components of the Investigational Product formulation

          -  Participation in any clinical research study evaluating another investigational drug
             or therapy within 30 days or at least 5 half-lives (whichever is longer), of the
             investigational drug prior to the screening visit

          -  Any condition that would place the subject at risk, interfere with participation in
             the study

          -  History of a parasitic infection or recent (within the previous 6 months) travel to a
             parasitic endemic area

          -  Live/attenuated vaccinations within 12 weeks of screening or during the study

          -  Any subjects with planned elective surgery

          -  Sexually active men who are unwilling to utilize adequate contraception</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Nucleus Network - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Regeneron Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Sanofi</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is being conducted to assess the safety and tolerability of a single ascending
      intravenous (IV) dose of REGN846 in healthy volunteers.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01209793</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trial Management</name>
      <address>Regeneron Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>